Results: The recurrent disease was suspected in 47 patients and the biopsy was recommended. In 8 cases (TIC II), the biopsy was performed due to long-term post-treatment changes. Histological results proved STT recurrence in 45 patients; in 10 patients (8 with TIC II), biopsy revealed hypervascular granulation tissue, fl orid infl ammation and reactive changes. The sensitivity for dynamic contrast-enhanced MR examination was 100 %, specifi city 80 %, positive predictive value (PPV) 95.7 % and negative predictive value (NPV) 100 %. Conclusion: Our results indicate that TICs III, IV and V raise high suspicion of local tumor recurrence and require percutaneous imaging-guided biopsy. TIC of type II usually represents a pseudomass and the biopsy should be performed only in selected cases with increased risk of recurrent disease based on multidisciplinary approach. On the basis of literature review as well as our experiences we created a reliable algorithm proposed for diagnosing the residual or recurrent soft-tissue tumors (Tab. 2, Fig. 6, Ref. 20). Full Text in PDF www.elis.sk.
Malignant soft-tissue tumors (STTs) macroscopically mostly appear as good demarcated masses with presence of pseudocapsule, giving an impression of benign origin. This fact may result in inadequate margins and microscopic residual nodules discovered only at histological examination, and it may be these lesions that mostly account for the frequency of later local recurrence (1) . The detection of residual tumorous foci and local tumor recurrence is very diffi cult especially in apparent postsurgical and postirradiation changes in the surrouding tissue. Ultrasound and CT examinations are of limited value. MRI thus remains the most important method for studying and following up the residual or recurrent STTs.
The most important characteristic features of the lesion on MRI are the signal intensity (SI) and lesion confi guration. As a fi rst step for evaluating the recurrent STT, T2-weighted spin echo sequence (T2w TSE) is of highest value. T2-weighted spin echo sequence has to be associated with a fat suppression method (T2w TSE FS). The recurrent soft-tissue tumor appears as a high SI lesion in T2w TSE, whereas scars usually exhibit a typically low SI ( Fig. 1 ) because of their fi brous tissue content (2, 3, 4) . Some viable tumors containing a large amount of collagen (e.g. malignant fi brous histiocytoma, aggressive fi bromatosis and fi brosarcoma) can be therefore misdiagnosed on T2w images due to their lowsignal intensity. The high SI lesions without associated mass on T2w image may also cause diffi culties in differential diagnosis and can be mistaken for any tissue with large amount of water content, such as hematomas of variable age, hygromas, infl ammatory ( Fig. 2) and irradiation changes and granulation tissue. The return period to low SI varies with extent of surgical procedure, dose of irradiation, and individual conditions infl uencing the reparative process. This may take months even years. Vanel et al. described tumor recurrence in a 6-month period not visible retrospectively. Either the lesion was too small or it was overlooked because it exhibited the same signal intensity as infl ammatory changes and no clear mass effect (1) .
The presence of high-signal intensity mass in T2w TSE always raises suspicion of tumor recurrence. In this case, intravenous administration of paramagnetic contrast agent (gadolinium chelates) is required. Absence of postcontrast enhancement can usually exclude tumor recurrence. The only exceptions are partially enhancing tumors with almost complete necrosis and minimal extent of viable tumor tissue, and tumors with large nonenhancing mucoid or myxomatous components. Soft-tissue mass with high SI on T2w sequences, enhancing after intravenous injection of contrast medium, should be considered recurrent STT. However the differentiation of the infl ammatory pseudotumor and variable degree of post-treatment reactive changes from recurring disease remains a problem. In these cases, the dynamic contrast-enhanced MRI is the problem-solving technique. As this process is infl uenced by pathologic changes in tissues, the aim of dynamic contrast-enhanced (CE) MR imaging is to detect and depict the differences in early intravascular and interstitial distribution, (5) (6) (7) (8) (9) (10) (11) (12) . One of frequently used techniques is the region of interest (ROI) technique (13, 14) based on dynamic analysis and graphical expression of the timedependent enhancement values with obtaining time-to-intensity curves (TIC) (Fig. 3) . Active tumors show rapid enhancement in the early phase of vascularisation, whereas post-treatment changes enhance in the later period, almost after two and more minutes.
The basic principle of the dynamic CE study is to follow gadolinium pharmacokinetics after its intravenous administration. The main pieces of information obtained with this method are the characteristics of tissue vascularisation and perfusion, capillary permeability, and size and composition of interstitial space. Figure 4 shows the classifi cation of time-to-intensity curves. The main value of this technique is in the detection of residual or recurrent STT in the region of post-treatment changes, monitoring the treatment response after neoadjuvant chemotherapy, identifi cation of viable tumor areas before biopsy as well as in the differentiation of biological behavior of the tumorous tissue (benign versus malignant).
According to literature (15) , the evaluation of malignant potential of musculoskeletal lesions with slope of TICs was possible with levels of sensitivity and specifi city ranging from 72 % to 83 %, and 77 % to 89 %, respectively. An overlap was described among some highly vascularized or perfused benign lesions (such as capillary or high-fl ow hemangioma, myositis ossifi cans, abscess, granulation tissue, and occasionally, aggressive fi bromatosis, neurinoma and neurofi broma) and malignant tumors. Combined nonenhanced static and dynamic contrast-enhanced MR imaging demonstrate the best diagnostic performance in prediction of malignancy for STT (16). After surgery, chemotherapy and radiation therapy, a residual or recurrent tumor mass may be diffi cult to detect as clinically as with imaging methods. This is due to scar formation and early and later post-treatment changes such as infl ammation, presence of granulation tissue and development of fi brosis. Postsurgical scars tend to enhance within the fi st six months. After radiation therapy, irradiated normal tissue demonstrates patchy or diffuse enhancement during the fi rst nine months. After 10 to 18 months, the enhancement slowly decreases in a variable way.
On the basis of literature review as well as our experiences, we created a reliable algorithm proposed for diagnosing residual or recurrent soft-tissue tumors (Fig. 5) . The MR imaging follow up of patients with malignant soft-tissue tumor history, after surgical treatment, radiation therapy or chemotherapy should usually begin with a T2-weighted sequence. If there is a low-signal intensity area presenting typically fi brotic changes, the examination is considered negative and could be fi nished with recommendation of next follow-up after 6-12 months depending on the patient's clinical status. If diffuse high-signal intensity without a mass is seen, T1-weighted sequences both without and with contrast injection are required. If no contrast enhancement is present, a usual follow-up after 6-12 months is recommended. In case of static postcontrast enhancement, dynamic contrast-enhanced study in shorter time period is useful for excluding pseudomass. According to recent literature data, in these cases we always perform dynamic contrast-enhanced study followed by subtraction method. Dynamic contrast-enhanced MR imaging is the method of fi rst choice, when on initial T2-weighted sequence a mass with high-signal intensity appears. Masses with TICs showing a slow increase in enhancement (low vascularization and low perfusion) should be observed by regular follow-ups but those with an early and fast enhancement increase (high perfusion and vascularization rates) have to undergo biopsy and treatment. Fig. 4 . Classifi cation of time-to-intensity curves: type I -no enhancement, type II -gradual increase in enhancement, type III -rapid initial enhancement followed by plateau, type IV -rapid initial enhancement followed by a wash-out phase, type V -rapid initial enhancement followed by sustained late enhancement (30). Sensitivity 72-83 %, specifi city 77-89 % (14). gery, radiotherapy or chemotherapy). There were 54 males (median age 51 years) and 41 females (median age 53 years). Patients were classifi ed according to fi ve types of TIC (Tab. 1). The technique of dynamic contrast-enhanced MR examination requires a bolus of gadolinium contrast medium in amount of 0,1-0,2 ml/kg followed immediately by saline fl ush of about 20 ml at an injection rate of 3-5-ml/sec. Use of a power injector is preferable. T1-weighted 3D turbo fl ash and/or fat suppressed T1-weighted 3D turbo fl ash (Siemens, Erlangen, Germany) sequences followed with subtraction imaging are usually performed. Although fat saturation might be useful, in practice this is not necessarily done, as fat is adequately suppressed by most postprocessing techniques, e.g. in subtraction and fi rst-pass images (11, 12, 17,1 8) . The delay between the native sequence and fi rst-pass dynamic postcontrast sequence is about 7-15 seconds (11). The range of temporal resolution is one image per 3.5-7 seconds till 90-180 (240) seconds after contrast administration, matrix size 128x128, the number of measurements of 5-10 is thus mandatory. An important role belongs to the qualitative "subtraction method", in which the precontrast image is subsequently subtracted from all postcontrast image series of the dynamic study. In this way, discrete, early enhancing areas are detected, and high signals from fat and hemorrhage are nullifi ed (15) . It helps to evaluate the time interval between the onset of arterial and tumoral enhancement and to detect the viable part of the lesion. This is of high importance for indicating the best site for biopsy or to determine the degree of response to preoperative chemotherapy (6, 19, 20) .
Materials and methods

From March 2002 till December 2009 we examined 95 patients with malignant soft-tissue tumors after receiving treatment (sur-
Results
Biopsy was performed altogether in 55 of 95 examined patients with malignant soft-tissue tumor after receiving treatment (TIC III, IV, V and 8 with TIC II). Due to TIC classifi cation, recurrent disease was suspected in 47 patients and the biopsy was required. In 8 cases (TIC II), the biopsy was performed due to long-term post-treatment changes. Histology proved STT recurrence in 45 patients; in 2 patients, hypervascular granulation tissue was found. The 8 TIC II classifi ed patients turned out to be fl orid infl ammatory and reactive changes in histological results. Of the 45 STT recurrent patients, 27 were males and 18 females. Histological outcomes proved 19 malignant fi brous histiocytomas (Fig. 6 ), 9 liposarcomas, 8 synovial sarcomas, 3 chondrosarcomas (soft tissue), 3 leiomyosarcomas, 2 fi brosarcomas and 1 lymfangiosarcoma. The most common locality was in extremities 36 (80 %), then retroperitoneum 7 (15.6 %), and 2 STTs were localized (4.4 %) in viscera. This means sensitivity for dynamic contrast-enhanced MR examination of 100 %, specifi city of 80 %, positive predictive value (PPV) of 95.7 %, and negative predictive value (NPV) of 100 %. Test of reliability for dynamic CE study in diagnosis of STT recurrence compared with histological results is shown in Table 2 .
Discussion
Dynamic contrast-enhanced MR imaging followed by image subtraction and qualitative analysis by TICs: 1. provides clinically useful information about vascularisation and perfusion of tissue, its capillary permeability, and size and composition of interstitial space, 2. allows narrowing down the spectrum of differential diagnosis, 3. contributes to the prediction of biological behavior of the lesion, 4. is helpful for identifying viable areas of the tumor, the fact of which is of highest importance for planning the biopsy procedures, 5. is useful in achieving qualitative assessment of tumor response during and after neoadjuvant or adjuvant chemotherapy, 6. depicts residual or recurrent soft-tissue tumor foci with relatively high sensitivity and allows their differentiation against post- treatment changes such as fi brosis, infl ammatory pseudomass, hematomas and hygromas.
Our results indicate that TICs III, IV and V highly raise suspicion of local tumor recurrence and require percutaneous imaginingguided biopsy. TIC type II usually represents pseudomass and the biopsy should be performed only in selected cases with increased risk of recurrent disease based on multidisciplinary approach.
